The Novel Potential Therapeutic Utility of Montelukast in Alleviating Autistic Behavior Induced by Early Postnatal Administration of Thimerosal in Mice
Autor: | Ola A. Hussein, I E M Ashry, Lobna A. Abdelzaher |
---|---|
Rok vydání: | 2020 |
Předmět: |
Cyclopropanes
0301 basic medicine alpha7 Nicotinic Acetylcholine Receptor Alpha (ethology) Nerve Tissue Proteins Inflammation Acetates Sulfides Pharmacology Hippocampus Mice 03 medical and health sciences Cellular and Molecular Neuroscience 0302 clinical medicine Downregulation and upregulation medicine Animals Autistic Disorder Social Behavior Montelukast business.industry Leukotriene receptor Thimerosal Transcription Factor RelA Antagonist Cell Biology General Medicine 030104 developmental biology Nicotinic agonist Animals Newborn Montelukast Sodium Quinolines Growth and Development medicine.symptom business 030217 neurology & neurosurgery medicine.drug |
Zdroj: | Cellular and Molecular Neurobiology. 41:129-150 |
ISSN: | 1573-6830 0272-4340 |
DOI: | 10.1007/s10571-020-00841-2 |
Popis: | BACKGROUND AND AIM: Thimerosal (THIM) is a mercury-containing preservative widely used in many biological and medical products including many vaccines. It has been accused of being a possible etiological factor for some neurodevelopmental disorders such as autistic spectrum disorders (ASDs). In our study, the potential therapeutic effect of montelukast, a leukotriene receptor antagonist used to treat seasonal allergies and asthma, on THIM mice model (ASDs model) was examined.Newborn mice were randomly distributed into three groups: (Group 1) Control (Cont.) group received saline injections. (Group 2) THIM-treated (THIM) group received THIM intramuscular (IM) at a dose of 3000 μg Hg/kg on postnatal days 7, 9, 11, and 15. (Group 3) Montelukast-treated (Monte) group received THIM followed by montelukast sodium (10 mg/kg/day) intraperitoneal (IP) for 3 weeks. Mice were evaluated for growth development, social interactions, anxiety, locomotor activity, and cognitive function. Brain histopathology, alpha 7 nicotinic acetylcholine receptors (α7nAChRs), nuclear factor kappa B p65 (NF-κB p65), apoptotic factor (Bax), and brain injury markers were evaluated as well.THIIM significantly impaired social activity and growth development. Montelukast mitigated THIM-induced social deficit probably through α7nAChRs upregulation, NF-κB p65, Bax, and brain injury markers downregulation, thus suppressing THIM-induced neuronal toxicity and inflammation.Neonatal exposure to THIM can induce growth retardation and abnormal social interactions similar to those observed in ASDs. Some of these abnormalities could be ameliorated by montelukast via upregulation of α7nAChRs that inhibited NF-κB activation and significant suppression of neuronal injury and the associated apoptosis. |
Databáze: | OpenAIRE |
Externí odkaz: |